{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:24:29Z","timestamp":1791465869902,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772198"],"award-info":[{"award-number":["81772198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10302206"],"award-info":[{"award-number":["2018ZX10302206"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"publisher","award":["cstc2020jcyj-msxmX0389"],"award-info":[{"award-number":["cstc2020jcyj-msxmX0389"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some cytokine signaling pathways can interact with interferon (IFN)-\u03b1 pathway and thus regulate cell responses to IFN-\u03b1. Levels of the pro-inflammatory cytokine interleukin-17A (IL-17A) were found to be elevated in both the peripheral blood and liver in chronic hepatitis B (CHB) patients. However, how IL-17A affects the anti-HBV activity of IFN-\u03b1 remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effects of IL-17A on anti-HBV activity of IFN-\u03b1 were evaluated in HBV-expressing HepG2 cells (HepG2-HBV1.3) with IL-17A pretreatment and IFN-\u03b1 stimulation. Culture supernatant levels of HBsAg, HBeAg, and HBV DNA, or intracellular expression of HBsAg and HBcAg were detected by ELISA, real-time quantitative PCR (RT-qPCR), or western blotting (WB). The expression of canonical IFN-\u03b1 signaling pathway components, including the interferon-\u03b1\/\u03b2 receptor (IFNAR), Janus Kinase 1 (JAK1), Tyrosine Kinase 2 (TYK2), the Interferon Stimulated Gene Factor 3 complex (ISGF3) and IFN-stimulated genes (ISGs), was also examined by RT-qPCR, Immunofluorescence or WB. The effects of IL-17A were further investigated by the suppression of the IL-17A pathway with a TRAF6 inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to IFN-\u03b1 stimulation alone, IL-17A pretreatment followed by IFN-\u03b1 stimulation increased the levels of HBsAg, HBeAg, and HBV DNA, and decreased the levels of ISGF3 complex (phosphorylated (p)-signal transducer and activator of transcription (STAT1)\/p-STAT2\/IRF9) and antiviral-related ISGs (ISG15, ISG20 and Mx1). Interestingly, IL-17A pretreatment increased the expression of suppressor of cytokine signaling (SOCS) 1, SOCS3 and USP18, which were also the ISGs negatively regulating activity of ISGF3. Moreover, IFNAR1 protein expression declined more sharply in the group with IL-17A pretreatment than in the group with IFN-\u03b1 stimulation alone. Blocking the IL-17A pathway reversed the effects of IL-17A on the IFN-\u03b1-induced activation of ISGF3 and anti-HBV efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results demonstrate that IL-17A pretreatment could attenuate IFN-\u03b1-induced anti-HBV activity by upregulating negative regulators of the critical transcriptional ISGF3 complex. Thus, this might be a potential target for improving response to IFN-\u03b1 therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-022-01753-x","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T07:02:57Z","timestamp":1644476577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells"],"prefix":"10.1186","volume":"19","author":[{"given":"Jiaxuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"1753_CR1","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/hep.27323","volume":"61","author":"B Rehermann","year":"2015","unstructured":"Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology (Baltimore, MD). 2015;61:712\u201321.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"1753_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cld.2016.06.002","volume":"20","author":"MA Konerman","year":"2016","unstructured":"Konerman MA, Lok AS. Interferon Treatment for Hepatitis B. Clin Liver Dis. 2016;20:645\u201365.","journal-title":"Clin Liver Dis"},{"key":"1753_CR3","doi-asserted-by":"crossref","unstructured":"APASL. Abstracts of the 26th ANNUAL CONFERENce of APASL, February 15\u201319, 2017, Shanghai, China. Hepatology international. 2017;11.","DOI":"10.1007\/s12072-016-9783-9"},{"key":"1753_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coviro.2016.01.001","volume":"16","author":"JR Teijaro","year":"2016","unstructured":"Teijaro JR. Type I interferons in viral control and immune regulation. Curr Opin Virol. 2016;16:31\u201340.","journal-title":"Curr Opin Virol"},{"key":"1753_CR5","doi-asserted-by":"crossref","unstructured":"Tian Z, Shen X, Feng H, Gao B. IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway. J Immunol (Baltimore, Md : 1950). 2000;165:3959\u201365.","DOI":"10.4049\/jimmunol.165.7.3959"},{"key":"1753_CR6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1096\/fj.00-0908fje","volume":"15","author":"F Hong","year":"2001","unstructured":"Hong F, Nguyen VA, Gao B. Tumor necrosis factor alpha attenuates interferon alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J. 2001;15:1595\u20137.","journal-title":"FASEB J"},{"key":"1753_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0014-5793(00)01905-0","volume":"480","author":"X Shen","year":"2000","unstructured":"Shen X, Hong F, Nguyen VA, Gao B. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett. 2000;480:132\u20136.","journal-title":"FEBS Lett"},{"key":"1753_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","volume":"38","author":"N Amatya","year":"2017","unstructured":"Amatya N, Garg AV, Gaffen SL. IL-17 signaling: the Yin and the Yang. Trends Immunol. 2017;38:310\u201322.","journal-title":"Trends Immunol"},{"key":"1753_CR9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/liv.14438","volume":"40","author":"K Zhang","year":"2020","unstructured":"Zhang K, Liu Y, Yang X, Sun H, Shu X, Zhang Y, et al. HBV promotes the recruitment of IL-17 secreting T cells via chemokines CCL22 and CCL17. Liver Int. 2020;40:1327\u201338.","journal-title":"Liver Int"},{"key":"1753_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.imlet.2012.12.001","volume":"149","author":"B Yang","year":"2013","unstructured":"Yang B, Wang Y, Zhao C, Yan W, Che H, Shen C, et al. Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol Lett. 2013;149:41\u20139.","journal-title":"Immunol Lett"},{"key":"1753_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/hep.23273","volume":"51","author":"JY Zhang","year":"2010","unstructured":"Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology (Baltimore, MD). 2010;51:81\u201391.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"1753_CR12","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/liv.12701","volume":"35","author":"C Yu","year":"2015","unstructured":"Yu C, Gong X, Yang Q, Lian J, Xu K, Ruan B, et al. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B. Liver Int. 2015;35:1549\u201356.","journal-title":"Liver Int"},{"key":"1753_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1089\/vim.2015.0024","volume":"28","author":"H Feng","year":"2015","unstructured":"Feng H, Yin J, Han Y-P, Zhou X-Y, Chen S, Yang L, et al. Sustained changes of treg and Th17 cells during interferon-\u03b1 therapy in patients with chronic hepatitis B. Viral Immunol. 2015;28:412\u20137.","journal-title":"Viral Immunol"},{"key":"1753_CR14","doi-asserted-by":"crossref","unstructured":"Luo L, Jiang L, Tian Z, Zhang X. The serum interleukin-26 level is a potential biomarker for chronical hepatitis B. Medicine. 2020;99:e18462.","DOI":"10.1097\/MD.0000000000018462"},{"key":"1753_CR15","first-page":"416","volume":"21","author":"J Zhang","year":"2017","unstructured":"Zhang J, Ying H, Wei L, Hong LJ. Effect of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cell. Eur Rev Med Pharmacol Sci. 2017;21:416\u201320.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1753_CR16","doi-asserted-by":"publisher","first-page":"36551","DOI":"10.1038\/srep36551","volume":"6","author":"Q Huang","year":"2016","unstructured":"Huang Q, Duan L, Qian X, Fan J, Lv Z, Zhang X, et al. IL-17 promotes angiogenic factors IL-6, IL-8, and vegf production via Stat1 in lung adenocarcinoma. Sci Rep. 2016;6:36551.","journal-title":"Sci Rep"},{"key":"1753_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/1471-2164-11-226","volume":"11","author":"T Sparna","year":"2010","unstructured":"Sparna T, R\u00e9tey J, Schmich K, Albrecht U, Naumann K, Gretz N, et al. Genome-wide comparison between IL-17 and combined TNF-alpha\/IL-17 induced genes in primary murine hepatocytes. BMC Genom. 2010;11:226.","journal-title":"BMC Genom"},{"key":"1753_CR18","unstructured":"Tang N, Huang A-l, Zhang B-q, Yan G, Xiang M-q, Pu D, et al. Construction of recombinant eukaryotic expression plasmid containing 1.3-fold-overlength genome of HBV and its expression in HepG2 cells. Zhonghua Gan Zang Bing Za Zhi. 2003;11:464\u20136."},{"key":"1753_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7150\/ijbs.62106","volume":"18","author":"J Wei","year":"2022","unstructured":"Wei J, Shi Y, Zou C, Zhang H, Peng H, Wang S, et al. Cellular Id1 inhibits hepatitis B virus transcription by interacting with the novel covalently closed circular DNA-binding protein E2F4. Int J Biol Sci. 2022;18:65\u201381.","journal-title":"Int J Biol Sci"},{"key":"1753_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-016-0888-7","volume":"14","author":"G Yu","year":"2016","unstructured":"Yu G, Chen X, Chen S, Ye W, Hou K, Liang M. MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells. J Transl Med. 2016;14:122.","journal-title":"J Transl Med"},{"key":"1753_CR21","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1084\/jem.191.7.1233","volume":"191","author":"R Schwandner","year":"2000","unstructured":"Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med. 2000;191:1233\u201340.","journal-title":"J Exp Med"},{"key":"1753_CR22","doi-asserted-by":"crossref","unstructured":"Lu Y-J, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 2008;4:e1000159.","DOI":"10.1371\/journal.ppat.1000159"},{"key":"1753_CR23","doi-asserted-by":"crossref","unstructured":"Hamada S, Umemura M, Shiono T, Tanaka K, Yahagi A, Begum MD, et al. IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver. J Immunol (Baltimore, Md : 1950). 2008;181:3456\u201363.","DOI":"10.4049\/jimmunol.181.5.3456"},{"key":"1753_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20081463","volume":"206","author":"HR Conti","year":"2009","unstructured":"Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206:299\u2013311.","journal-title":"J Exp Med"},{"key":"1753_CR25","doi-asserted-by":"crossref","unstructured":"Ma WT, Yao XT, Peng Q, Chen DK. The protective and pathogenic roles of IL-17 in viral infections: friend or foe? Open Biol. 2019;9:190109.","DOI":"10.1098\/rsob.190109"},{"key":"1753_CR26","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/jid.2009.399","volume":"130","author":"S Kagami","year":"2010","unstructured":"Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130:1373\u201383.","journal-title":"J Invest Dermatol"},{"key":"1753_CR27","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1136\/gut.2007.135053","volume":"57","author":"T Kobayashi","year":"2008","unstructured":"Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, et al. IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn\u2019s disease. Gut. 2008;57:1682\u20139.","journal-title":"Gut"},{"key":"1753_CR28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","volume":"31","author":"N Martin-Orozco","year":"2009","unstructured":"Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787\u201398.","journal-title":"Immunity"},{"key":"1753_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/blood-2008-09-177360","volume":"114","author":"I Kryczek","year":"2009","unstructured":"Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114:357\u20139.","journal-title":"Blood"},{"key":"1753_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4049\/jimmunol.1201970","volume":"190","author":"L Hou","year":"2013","unstructured":"Hou L, Jie Z, Desai M, Liang Y, Soong L, Wang T, et al. Early IL-17 production by intrahepatic T cells is important for adaptive immune responses in viral hepatitis. J Immunol. 2013;190:621\u20139.","journal-title":"J Immunol"},{"key":"1753_CR31","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.4049\/jimmunol.181.7.4485","volume":"181","author":"AG Rowan","year":"2008","unstructured":"Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, O\u2019Farrelly C, et al. Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol. 2008;181:4485\u201394.","journal-title":"J Immunol"},{"key":"1753_CR32","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1097\/TP.0b013e31823817f5","volume":"92","author":"AB Seetharam","year":"2011","unstructured":"Seetharam AB, Borg BB, Subramanian V, Chapman WC, Crippin JS, Mohanakumar T. Temporal association between increased virus-specific Th17 response and spontaneous recovery from recurrent hepatitis C in a liver transplant recipient. Transplantation. 2011;92:1364\u201370.","journal-title":"Transplantation"},{"key":"1753_CR33","doi-asserted-by":"crossref","unstructured":"Li MH, Chen QQ, Zhang L, Lu HH, Sun FF, Zeng Z, et al. Association of cytokines with hepatitis B virus and its antigen. J Med Virol. 2020.","DOI":"10.1002\/jmv.26301"},{"key":"1753_CR34","first-page":"385","volume":"27","author":"L Wang","year":"2011","unstructured":"Wang L, Chen S, Xu K. IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int J Mol Med. 2011;27:385\u201392.","journal-title":"Int J Mol Med"},{"key":"1753_CR35","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/jvh.13352","volume":"27","author":"H Zhang","year":"2020","unstructured":"Zhang H, Yan X, Yang C, Zhan Q, Fu Y, Luo H, et al. Intrahepatic T helper 17 cells recruited by hepatitis B virus X antigen-activated hepatic stellate cells exacerbate the progression of chronic hepatitis B virus infection. J Viral Hepat. 2020;27:1138\u201349.","journal-title":"J Viral Hepat"},{"key":"1753_CR36","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.4049\/jimmunol.1303432","volume":"193","author":"X Kong","year":"2014","unstructured":"Kong X, Sun R, Chen Y, Wei H, Tian Z. \u03b3\u03b4T cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance. J Immunol. 2014;193:1645\u201353.","journal-title":"J Immunol"},{"key":"1753_CR37","doi-asserted-by":"crossref","unstructured":"Wang B, Zhao X-P, Fan Y-C, Zhang J-J, Zhao J, Wang K. IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. Antivir Res. 2013;97:285\u201392.","DOI":"10.1016\/j.antiviral.2012.12.018"},{"key":"1753_CR38","doi-asserted-by":"crossref","unstructured":"Ribeiro CRdA, Martinelli KG, de Mello VdM, Baptista BdS, Dias NST, Paiva IA, et al. Cytokine, genotype, and viral load profile in the acute and chronic hepatitis B. Viral Immunol. 2020;33:620\u20137.","DOI":"10.1089\/vim.2020.0176"},{"issue":"4","key":"1753_CR39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1055\/s-0041-1730926","volume":"41","author":"N Li","year":"2021","unstructured":"Li N, Yamamoto G, Fuji H, Kisseleva T. Interleukin-17 in liver disease pathogenesis. Semin Liver Dis. 2021;41(4):507\u201315.","journal-title":"Semin Liver Dis"},{"key":"1753_CR40","doi-asserted-by":"crossref","unstructured":"Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9(1):e001895.","DOI":"10.1136\/jitc-2020-001895"},{"key":"1753_CR41","doi-asserted-by":"publisher","first-page":"46614","DOI":"10.1074\/jbc.M407082200","volume":"279","author":"KGS Kumar","year":"2004","unstructured":"Kumar KGS, Krolewski JJ, Fuchs SY. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J Biol Chem. 2004;279:46614\u201320.","journal-title":"J Biol Chem"},{"key":"1753_CR42","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1083\/jcb.200706034","volume":"179","author":"KGS Kumar","year":"2007","unstructured":"Kumar KGS, Barriere H, Carbone CJ, Liu J, Swaminathan G, Xu P, et al. Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol. 2007;179:935\u201350.","journal-title":"J Cell Biol"},{"key":"1753_CR43","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1128\/MCB.00478-09","volume":"29","author":"J Liu","year":"2009","unstructured":"Liu J, Carvalho LP, Bhattacharya S, Carbone CJ, Kumar KGS, Leu NA, et al. Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol Cell Biol. 2009;29:6401\u201312.","journal-title":"Mol Cell Biol"},{"key":"1753_CR44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1128\/MCB.01154-10","volume":"31","author":"H Zheng","year":"2011","unstructured":"Zheng H, Qian J, Varghese B, Baker DP, Fuchs S. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol. 2011;31:710\u201320.","journal-title":"Mol Cell Biol"},{"key":"1753_CR45","doi-asserted-by":"publisher","first-page":"35733","DOI":"10.1074\/jbc.M111.263608","volume":"286","author":"H Zheng","year":"2011","unstructured":"Zheng H, Qian J, Baker DP, Fuchs SY. Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor. J Biol Chem. 2011;286:35733\u201341.","journal-title":"J Biol Chem"},{"key":"1753_CR46","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221\u20138.","journal-title":"Science"},{"key":"1753_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2017.10.003","volume":"147","author":"M Han","year":"2017","unstructured":"Han M, Li Y, Wu W, Zhang Y, Yan W, Luo X, et al. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. Antivir Res. 2017;147:75\u201385.","journal-title":"Antivir Res"},{"key":"1753_CR48","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1016\/j.jmb.2013.09.041","volume":"425","author":"DJ Morales","year":"2013","unstructured":"Morales DJ, Lenschow DJ. The antiviral activities of ISG15. J Mol Biol. 2013;425:4995\u20135008.","journal-title":"J Mol Biol"},{"key":"1753_CR49","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.antiviral.2014.01.021","volume":"104","author":"I-H Park","year":"2014","unstructured":"Park I-H, Kwon Y-C, Ryu W-S, Ahn B-Y. Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L. Antivir Res. 2014;104:118\u201327.","journal-title":"Antivir Res"},{"key":"1753_CR50","doi-asserted-by":"crossref","unstructured":"Liu Y, Nie H, Mao R, Mitra B, Cai D, Yan R, et al. Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. PLoS Pathog. 2017;13:e1006296.","DOI":"10.1371\/journal.ppat.1006296"},{"key":"1753_CR51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/hep.25608","volume":"56","author":"N Li","year":"2012","unstructured":"Li N, Zhang L, Chen L, Feng W, Xu Y, Chen F, et al. MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen. Hepatology (Baltimore, MD). 2012;56:803\u201311.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"1753_CR52","doi-asserted-by":"publisher","first-page":"9976","DOI":"10.1074\/jbc.M109078200","volume":"277","author":"MP Malakhov","year":"2002","unstructured":"Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang D-E. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem. 2002;277:9976\u201381.","journal-title":"J Biol Chem"},{"key":"1753_CR53","doi-asserted-by":"crossref","unstructured":"Li L, Lei QS, Zhang SJ, Kong LN, Qin B. Suppression of USP18 potentiates the anti-HBV activity of interferon alpha in HepG2.2.15 cells via JAK\/STAT signaling. PLoS One. 2016;11:e0156496.","DOI":"10.1371\/journal.pone.0156496"},{"key":"1753_CR54","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nri2093","volume":"7","author":"A Yoshimura","year":"2007","unstructured":"Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454\u201365.","journal-title":"Nat Rev Immunol"},{"key":"1753_CR55","doi-asserted-by":"publisher","first-page":"35056","DOI":"10.1074\/jbc.273.52.35056","volume":"273","author":"MM Song","year":"1998","unstructured":"Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. 1998;273:35056\u201362.","journal-title":"J Biol Chem"},{"key":"1753_CR56","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1634\/stemcells.19-5-378","volume":"19","author":"DL Krebs","year":"2001","unstructured":"Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001;19:378\u201387.","journal-title":"Stem Cells"},{"key":"1753_CR57","doi-asserted-by":"publisher","first-page":"17409","DOI":"10.1073\/pnas.1904125116","volume":"116","author":"X Wang","year":"2019","unstructured":"Wang X, Sun R, Hao X, Lian Z-X, Wei H, Tian Z. IL-17 constrains natural killer cell activity by restraining IL-15-driven cell maturation via SOCS3. Proc Natl Acad Sci USA. 2019;116:17409\u201318.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1753_CR58","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","volume":"129","author":"RM Onishi","year":"2010","unstructured":"Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129:311\u201321.","journal-title":"Immunology"},{"key":"1753_CR59","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jmv.25382","volume":"91","author":"K Yang","year":"2019","unstructured":"Yang K, Guan S, Zhang H, Chen Z. Induction of interleukin 6 impairs the anti-HBV efficiency of IFN-\u03b1 in human hepatocytes through upregulation of SOCS3. J Med Virol. 2019;91:803\u201312.","journal-title":"J Med Virol"},{"key":"1753_CR60","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1128\/JVI.02557-15","volume":"90","author":"SA MacParland","year":"2016","unstructured":"MacParland SA, Ma X-Z, Chen L, Khattar R, Cherepanov V, Selzner M, et al. Lipopolysaccharide and tumor necrosis factor alpha inhibit interferon signaling in hepatocytes by increasing ubiquitin-like protease 18 (USP18) expression. J Virol. 2016;90:5549\u201360.","journal-title":"J Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-022-01753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-022-01753-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-022-01753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T23:33:52Z","timestamp":1666481632000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-022-01753-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1186\/s12985-022-01753-x","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}